Trial Profile

ABC-04 a Phase 1B Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 27 Feb 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selumetinib (Primary) ; Cisplatin; Gemcitabine
Indications Biliary cancer; Gallbladder cancer
Focus Adverse reactions
Acronyms ABC-04

Most Recent Events

25 Jan 2020 Results (N=994), post hoc analysis evaluated differences by sex in the frequency of adverse events and overall survival and its impact on progression-free survival /recurrence-free survival in biliary tract cancer, presented at the 2020 Gastrointestinal Cancers Symposium
10 May 2016 Status changed from active, no longer recruiting to completed.
26 Sep 2013 Planned end date changed from 1 Aug 2013 to 1 Jan 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com